Literature DB >> 19258508

NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.

Erin Muhlbradt1, Ekaterina Asatiani, Elizabeth Ortner, Antai Wang, Edward P Gelmann.   

Abstract

NKX3.1 is a homeobox gene that codes for a haploinsufficient prostate cancer tumor suppressor. NKX3.1 protein levels are down-regulated in the majority of primary prostate cancer tissues. NKX3.1 expression in PC-3 cells increased insulin-like growth factor binding protein-3 (IGFBP-3) mRNA expression 10-fold as determined by expression microarray analysis. In both stably and transiently transfected PC-3 cells and in LNCaP cells, NKX3.1 expression increased IGFBP-3 mRNA and protein expression. In prostates of Nkx3.1 gene-targeted mice Igfbp-3 mRNA levels correlated with Nkx3.1 copy number. NKX3.1 expression in PC-3 cells attenuated the ability of insulin-like growth factor-I (IGF-I) to induce phosphorylation of type I IGF receptor (IGF-IR), insulin receptor substrate 1, phosphatidylinositol 3-kinase, and AKT. The effect of NKX3.1 on IGF-I signaling was not seen when cells were exposed to long-R3-IGF-I, an IGF-I variant peptide that does not bind to IGFBP-3. Additionally, small interfering RNA-induced knockdown of IGFBP-3 expression partially reversed the attenuation of IGF-IR signaling by NKX3.1 and abrogated NKX3.1 suppression of PC-3 cell proliferation. Thus, there is a close relationship in vitro and in vivo between NKX3.1 and IGFBP-3. The growth-suppressive effects of NKX3.1 in prostate cells are mediated, in part, by activation of IGFBP-3 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19258508      PMCID: PMC3740340          DOI: 10.1158/0008-5472.CAN-08-3022

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

Authors:  A P Chokkalingam; M Pollak; C M Fillmore; Y T Gao; F Z Stanczyk; J Deng; I A Sesterhenn; F K Mostofi; T R Fears; M P Madigan; R G Ziegler; J F Fraumeni; A W Hsing
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-05       Impact factor: 4.254

2.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.

Authors:  S M Harman; E J Metter; M R Blackman; P K Landis; H B Carter
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

3.  The smooth muscle gamma-actin gene promoter is a molecular target for the mouse bagpipe homologue, mNkx3-1, and serum response factor.

Authors:  J A Carson; R A Fillmore; R J Schwartz; W E Zimmer
Journal:  J Biol Chem       Date:  2000-12-15       Impact factor: 5.157

4.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Authors:  P Stattin; A Bylund; S Rinaldi; C Biessy; H Déchaud; U H Stenman; L Egevad; E Riboli; G Hallmans; R Kaaks
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

5.  Loss of function and inhibitory effects of human CSX/NKX2.5 homeoprotein mutations associated with congenital heart disease.

Authors:  H Kasahara; B Lee; J J Schott; D W Benson; J G Seidman; C E Seidman; S Izumo
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

6.  Expression studies and mutational analysis of the androgen regulated homeobox gene NKX3.1 in benign and malignant prostate epithelium.

Authors:  D K Ornstein; M Cinquanta; S Weiler; P H Duray; M R Emmert-Buck; C D Vocke; W M Linehan; J A Ferretti
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

7.  Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene.

Authors:  T L Wood; L E Rogler; M E Czick; A G Schuller; J E Pintar
Journal:  Mol Endocrinol       Date:  2000-09

8.  Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex.

Authors:  G E Walker; E M Wilson; D Powell; Y Oh
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

9.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.

Authors:  C Bowen; L Bubendorf; H J Voeller; R Slack; N Willi; G Sauter; T C Gasser; P Koivisto; E E Lack; J Kononen; O P Kallioniemi; E P Gelmann
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

10.  Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1.

Authors:  Mark C Markowski; Cai Bowen; Edward P Gelmann
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

View more
  10 in total

1.  NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.

Authors:  Cai Bowen; Tian Zheng; Edward P Gelmann
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

2.  Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3.

Authors:  J Musil; L Kutinova; K Zurkova; P Hainz; K Babiarova; J Krystofova; S Nemeckova
Journal:  Cancer Gene Ther       Date:  2014-02-21       Impact factor: 5.987

3.  CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.

Authors:  Cai Bowen; Maho Shibata; Hailan Zhang; Sarah K Bergren; Michael M Shen; Edward P Gelmann
Journal:  Cancer Res       Date:  2020-09-17       Impact factor: 12.701

4.  Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer.

Authors:  Erin Muhlbradt; Jing Ma; Gianluca Severi; Elizabeth Ortner; Vanessa Hayes; Hoa N Hoang; Meir Stampfer; Graham Giles; Michael Pollak; Edward P Gelmann
Journal:  Genes Cancer       Date:  2013-11

Review 5.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

6.  IGFBP-3 is a metastasis suppression gene in prostate cancer.

Authors:  Hemal H Mehta; Qinglei Gao; Colette Galet; Vladislava Paharkova; Junxiang Wan; Jonathan Said; Joanne J Sohn; Gregory Lawson; Pinchas Cohen; Laura J Cobb; Kuk-Wha Lee
Journal:  Cancer Res       Date:  2011-06-22       Impact factor: 12.701

7.  Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.

Authors:  Cai Bowen; Michael C Ostrowski; Gustavo Leone; Edward P Gelmann
Journal:  Cancer Res       Date:  2019-06-18       Impact factor: 12.701

8.  Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas.

Authors:  Hong-Qing Cai; Ang-Si Liu; Min-Jie Zhang; Hou-Jie Liu; Xiao-Li Meng; Hai-Peng Qian; Jing-Hai Wan
Journal:  Front Oncol       Date:  2020-05-22       Impact factor: 6.244

9.  Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice.

Authors:  Erin E Martinez; Philip D Anderson; Monica Logan; Sarki A Abdulkadir
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

10.  YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.

Authors:  Jiangfeng Li; Haiyun Xie; Yufan Ying; Hong Chen; Huaqing Yan; Liujia He; Mingjie Xu; Xin Xu; Zhen Liang; Ben Liu; Xiao Wang; Xiangyi Zheng; Liping Xie
Journal:  Mol Cancer       Date:  2020-10-29       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.